A detailed history of Interchange Capital Partners, LLC transactions in Amgen Inc stock. As of the latest transaction made, Interchange Capital Partners, LLC holds 1,570 shares of AMGN stock, worth $432,409. This represents 0.18% of its overall portfolio holdings.

Number of Shares
1,570
Previous 1,638 4.15%
Holding current value
$432,409
Previous $511,000 1.17%
% of portfolio
0.18%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$309.38 - $337.38 $21,037 - $22,941
-68 Reduced 4.15%
1,570 $505,000
Q2 2024

Jul 31, 2024

BUY
$262.75 - $319.31 $430,384 - $523,029
1,638 New
1,638 $511,000
Q3 2023

Nov 13, 2023

SELL
$218.65 - $271.46 $115,884 - $143,873
-530 Reduced 34.82%
992 $266,000
Q2 2023

Aug 08, 2023

SELL
$214.27 - $253.37 $456,823 - $540,184
-2,132 Reduced 58.35%
1,522 $337,000
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $405,518 - $494,259
1,796 Added 96.66%
3,654 $883,000
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $41,912 - $53,254
-183 Reduced 8.97%
1,858 $487,000
Q3 2022

Nov 07, 2022

BUY
$224.46 - $253.15 $4,264 - $4,809
19 Added 0.94%
2,041 $460,000
Q2 2022

Aug 05, 2022

SELL
$230.71 - $256.74 $12,227 - $13,607
-53 Reduced 2.55%
2,022 $491,000
Q1 2022

May 13, 2022

SELL
$219.27 - $242.57 $50,870 - $56,276
-232 Reduced 10.06%
2,075 $501,000
Q4 2021

Feb 04, 2022

BUY
$198.88 - $227.6 $159,899 - $182,990
804 Added 53.49%
2,307 $519,000
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $9,976 - $11,688
-47 Reduced 3.03%
1,503 $319,000
Q2 2021

Aug 16, 2021

SELL
$233.58 - $259.14 $302,953 - $336,104
-1,297 Reduced 45.56%
1,550 $377,000
Q1 2021

May 05, 2021

SELL
$221.91 - $258.6 $128,042 - $149,212
-577 Reduced 16.85%
2,847 $858,000
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $740,885 - $882,262
3,424 New
3,424 $787,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $147B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Interchange Capital Partners, LLC Portfolio

Follow Interchange Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Interchange Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Interchange Capital Partners, LLC with notifications on news.